Skip to content

AV Therapeutics, Inc.: 10-Q filed 2013-11-18

What AV Therapeutics, Inc. reported in its quarterly report filed 2013-11-18 (fiscal Q3 2013): 24 published measures, 81 facts as tagged in accession 0001185185-13-002524.

This filing

Form
10-Q (quarterly report)
Filed
2013-11-18
Fiscal period
fiscal Q3 2013
Accession
0001185185-13-002524 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AV Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-09-3074USD
At 2012-12-319,204USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-09-30-10,217USD
At 2012-12-31531USD
At 2011-12-3116,396USD
At 2010-12-310USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-09-3074USD
At 2012-12-314,204USD
At 2012-09-301,591USD
At 2011-12-3117,825USD
At 2011-11-130USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-12,636USD92
2013-01-01 to 2013-09-30-21,150USD273
2011-11-14 to 2013-09-30-66,619USD687
2012-01-01 to 2012-12-31-43,865USD366
2012-07-01 to 2012-09-30-15,832USD92
2012-01-01 to 2012-09-30-46,578USD274
2011-01-01 to 2011-12-31-1,604USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-09-30-21,732USD273
2011-11-14 to 2013-09-30-45,528USD687
2012-01-01 to 2012-09-30-31,234USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-09-300USD273
2011-11-14 to 2013-09-3018,000USD687
2012-01-01 to 2012-09-3013,000USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2013-07-01 to 2013-09-300USD92
2013-01-01 to 2013-09-300USD273
2011-11-14 to 2013-09-307,980USD687
2012-07-01 to 2012-09-300USD92
2012-01-01 to 2012-09-300USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-09-3017,602USD273
2011-11-14 to 2013-09-3063,602USD687
2012-01-01 to 2012-09-3028,000USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-09-300USD273
2011-11-14 to 2013-09-30-18,000USD687
2012-01-01 to 2012-09-30-13,000USD274

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2013-07-01 to 2013-09-300USD92
2013-01-01 to 2013-09-300USD273
2011-11-14 to 2013-09-300USD687
2012-07-01 to 2012-09-300USD92
2012-01-01 to 2012-09-300USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-09-300USD
At 2012-12-315,000USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-12,595USD92
2013-01-01 to 2013-09-30-21,297USD273
2011-11-14 to 2013-09-30-53,766USD687
2012-07-01 to 2012-09-30-2,832USD92
2012-01-01 to 2012-09-30-33,578USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-09-3074USD
At 2012-12-314,204USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-07-01 to 2013-09-3041USD92
2013-01-01 to 2013-09-3041USD273
2011-11-14 to 2013-09-3041USD687
2012-07-01 to 2012-09-300USD92
2012-01-01 to 2012-09-300USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-09-3010,291USD
At 2012-12-318,673USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2013-07-01 to 2013-09-3012,595USD92
2013-01-01 to 2013-09-3021,297USD273
2011-11-14 to 2013-09-3061,746USD687
2012-07-01 to 2012-09-302,832USD92
2012-01-01 to 2012-09-3033,578USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-09-3084,000,000shares
At 2012-12-3184,000,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-09-3048,002USD
At 2012-12-3137,600USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2013-09-300USD
At 2012-12-315,000USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2013-09-300USD
At 2012-12-310USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-12,636USD92
2013-01-01 to 2013-09-30-21,150USD273
2011-11-14 to 2013-09-30-53,619USD687
2012-07-01 to 2012-09-30-2,832USD92
2012-01-01 to 2012-09-30-33,578USD274

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2013-01-01 to 2013-09-300USD273
2012-01-01 to 2012-09-300USD274

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2013-01-01 to 2013-09-300USD273
2012-01-01 to 2012-09-300USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-01-01 to 2013-09-300USD273
2011-11-14 to 2013-09-3046,000USD687
2012-01-01 to 2012-09-3028,000USD274

Inspect the source

Entity
AV Therapeutics, Inc. / CIK 0001537293
Captured
SEC response SHA-256
8f1d9de3a91936bd8f297cc44f5fc9c526f99292fae3683af24f13a3b10f0811

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001537293.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))